Barinthus Biotherapeutics plc.
BRNS evidence brief
What we can confirm
- Market Cap:
- $30.2M
What it means
What to watch
Prepared research question
What matters most for BRNS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BRNS
Barinthus Biotherapeutics plc (BRNS) is a clinical-stage biotechnology company developing immune-modulating therapies for autoimmune and infectious diseases, with a lead candidate in Phase 1 for celiac disease and a pending merger that would rename the combined entity Clywedog Therapeutics Holdings, Inc.
Key risk: Sustained net losses
Market Cap
$30.2M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 5 clinical trials for Barinthus Biotherapeutics plc..
Barinthus Biotherapeutics plc (BRNS) is a clinical-stage biotechnology company developing immune-modulating therapies for autoimmune and infectious diseases, with a lead candidate in Phase 1 for celiac disease and a pending merger that would rename the combined entity Clywedog Therapeutics Holdings, Inc.
- Lead candidate VTP-1000, designed to restore immune non-responsiveness to gluten in celiac disease, is in Phase 1 clinical trial [sec_mda · as of 2026-08-06].
- VTP-300, a Phase 2 immunotherapeutic for chronic hepatitis B, uses ChAdOx and MVA viral vectors to increase disease-specific CD8+ T cells [sec_mda · as of 2026-08-06].
- Cash and equivalents were $59.3M as of 2026-06-30, with a net loss of -$10.6M for the period [latest reported financials].
- Accumulated deficit reached $320.2M as of June 30, 2026, and the company expects continued significant losses [sec_mda · as of 2026-08-06].
- A merger agreement is in place; the combined company will be renamed Clywedog Therapeutics Holdings, Inc. and trade under ticker CLYD, with closing expected in the second half of 2026 [sec_mda · as of 2026-08-06].
What works
- The SNAP-TI platform is designed to induce immune non-responsiveness to specific antigens, with potential applicability across multiple I&I indications beyond celiac disease [sec_mda · as of 2026-08-06].
- VTP-300 is a Phase 2 immunotherapeutic that is part of a treatment regimen aiming for functional cure in chronic hepatitis B, a large global market [sec_mda · as of 2026-08-06].
- The company has raised substantial capital, with gross proceeds of approximately $330.1M from equity and convertible notes, and has $59.6M in cash as of June 30, 2026 [sec_mda · as of 2026-08-06].
- The pending merger with Clywedog is expected to bring additional investment from OrbiMed and TPAV, LLC, and multiple clinical data milestones are anticipated within 18 months of closing [sec_mda · as of 2026-08-06].
What to weigh
- The company has incurred net losses in each annual and interim reporting period since 2023, with an accumulated deficit of $320.2M as of June 30, 2026 [sec_mda · as of 2026-08-06].
- Barinthus expects to continue incurring significant losses and negative cash flows for the foreseeable future, with expenses likely to increase as development progresses [sec_mda · as of 2026-08-06].
- The company is unable to predict when, if ever, material net cash inflows from product sales will commence, due to numerous development and regulatory uncertainties [sec_mda · as of 2026-08-06].
- The merger introduces integration risk and execution uncertainty, as the combined company will need to advance a portfolio spanning metabolic and autoimmune diseases while renaming and rebranding [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Lead candidate VTP-1000 is in Phase 1 for celiac disease
“Our lead candidate, VTP-1000, is designed to restore immune non-responsiveness to gluten in patients with celiac disease, and is currently being assessed in a Phase 1 clinical trial.”
SEC MD&A · August 6, 2026
VTP-300 is a Phase 2 immunotherapeutic for chronic hepatitis B
“VTP-300 is a Phase 2 immunotherapeutic treatment modality that is a component of a treatment regimen to establish functional cure in patients who are chronically infected by the hepa”
SEC MD&A · August 6, 2026
Accumulated deficit of $320.2M as of June 30, 2026
“June 30, 2026 and as of June 30, 2026, we had an accumulated deficit of $320.2 million.”
SEC MD&A · August 6, 2026
Merger to form Clywedog Therapeutics Holdings, Inc. expected to close in H2 2026
“Upon the closing of the transaction, the combined company will be renamed "Clywedog Therapeutics Holdings, Inc." and is expected to trade on the Nasdaq under the new ticker symbol "CLYD." The transaction is expected to close in the second half of 2026”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2019-02-10 · Phase 1 start for ChAdOx1 HBV vaccine (VTP-300 related) — A Phase 1 monotherapy study evaluating safety, tolerability, and immunogenicity of ChAdOx1 HBV in healthy and chronically infected participants.
- 2021-03-16 · Phase 2 start for HPV vaccine (VTP-200 related) — A Phase 1b/2 dose-ranging study of ChAdOx1 and MVA-vectored multigenotype hrHPV vaccine in women with low-grade cervical lesions.
- 2022-09-21 · Phase 2 start for another study (likely VTP-300 or related) — A Phase 2b open-label study to evaluate efficacy, safety, and tolerability of a candidate; specific candidate not fully detailed in chunk.
Risks & what to watch (4)›
Key risks
- Sustained net losses — Net losses in every period since 2023; accumulated deficit $320.2M as of June 30, 2026 [sec_mda · as of 2026-08-06].
- Uncertain cash flow timeline — Company cannot predict when material net cash inflows from product sales will begin [sec_mda · as of 2026-08-06].
- Merger integration risk — Pending merger with Clywedog introduces execution and integration uncertainties; closing expected H2 2026 [sec_mda · as of 2026-08-06].
- Clinical trial uncertainties — All product candidates are in early stages (Phase 1/2) with inherent risks of failure or delay [sec_mda · as of 2026-08-06].
What to watch
- Phase 1 data for VTP-1000 in celiac disease; no specific readout date provided [sec_mda · as of 2026-08-06].
- Phase 2 progress for VTP-300 in chronic hepatitis B; no specific readout date provided [sec_mda · as of 2026-08-06].
- Merger closing expected in the second half of 2026, which will rename the company to Clywedog Therapeutics Holdings, Inc. [sec_mda · as of 2026-08-06].
- Cash runway: $59.3M as of June 30, 2026, with ongoing net losses; monitor burn rate and any new financing [latest reported financials].
Sources: Catalysts · SEC MD&A · Generated October 6, 2026 · How we verify sources →
Run Barinthus Biotherapeutics plc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Barinthus Biotherapeutics plc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
14
Total value held
$7.9M
| Holder | Shares | Value |
|---|---|---|
| m&g plc | 5,197,349 | $5.2M |
| hsg holding ltd | 1,420,473 | $1.2M |
| glr partners, llc | 1,243,377 | $707K |
| dc funds, lp | 642,204 | $365K |
| rangeley capital, llc | 159,465 | $91K |
| renaissance technologies llc | 151,000 | $86K |
| johns hopkins university | 122,237 | $70K |
| citadel advisors llc | 118,996 | $68K |
| baird financial group, inc. | 105,961 | $60K |
| gts securities llc | 73,210 | $42K |
Showing top 10 of 14 institutional holders of Barinthus Biotherapeutics plc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 0.0%
- Days to cover
- 0.2
- Shares short
- 8,236
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BRNS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Barinthus Biotherapeutics plc.?
Barinthus Biotherapeutics plc (BRNS) is a clinical-stage biotechnology company developing immune-modulating therapies for autoimmune and infectious diseases, with a lead candidate in Phase 1 for celiac disease and a pending merger that would rename the combined entity Clywedog Therapeutics Holdings, Inc.
Who is the CEO of Barinthus Biotherapeutics plc.?
Mr. William James Enright MBA is the chief executive officer of Barinthus Biotherapeutics plc. (BRNS).
Where is Barinthus Biotherapeutics plc. headquartered?
Barinthus Biotherapeutics plc. (BRNS) is headquartered in Germantown, MD, United States.
What therapeutic areas does Barinthus Biotherapeutics plc. focus on?
Barinthus Biotherapeutics plc. develops therapies across Oncology, Immunology, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.